152 related articles for article (PubMed ID: 10874309)
21. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype.
Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM
Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218
[TBL] [Abstract][Full Text] [Related]
22. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.
Vandel P; Haffen E; Vandel S; Bonin B; Nezelof S; Sechter D; Broly F; Bizouard P; Dalery J
Eur J Clin Pharmacol; 1999 Nov; 55(9):659-65. PubMed ID: 10638395
[TBL] [Abstract][Full Text] [Related]
23. Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distributions.
Zackrisson AL; Holmgren P; Gladh AB; Ahlner J; Lindblom B
Eur J Clin Pharmacol; 2004 Oct; 60(8):547-52. PubMed ID: 15349706
[TBL] [Abstract][Full Text] [Related]
24. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
25. CYP2D6 genetic polymorphism in South Indian populations.
Naveen AT; Adithan C; Soya SS; Gerard N; Krishnamoorthy R
Biol Pharm Bull; 2006 Aug; 29(8):1655-8. PubMed ID: 16880622
[TBL] [Abstract][Full Text] [Related]
26. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.
Schaeffeler E; Schwab M; Eichelbaum M; Zanger UM
Hum Mutat; 2003 Dec; 22(6):476-85. PubMed ID: 14635107
[TBL] [Abstract][Full Text] [Related]
27. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.
de Leon J; Susce MT; Pan RM; Fairchild M; Koch WH; Wedlund PJ
J Clin Psychiatry; 2005 Jan; 66(1):15-27. PubMed ID: 15669884
[TBL] [Abstract][Full Text] [Related]
28. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
[TBL] [Abstract][Full Text] [Related]
29. CYP2D6 genotyping in patients on psychoactive drug therapy.
Topić E; Stefanović M; Ivanisević AM; Blazinić F; Culav J; Skocilić Z
Clin Chem Lab Med; 2000 Sep; 38(9):921-7. PubMed ID: 11097351
[TBL] [Abstract][Full Text] [Related]
30. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
[TBL] [Abstract][Full Text] [Related]
31. Frequency of five important CYP2D6 alleles within an Iranian population (Eastern Azerbaijan).
Kouhi H; Hamzeiy H; Barar J; Asadi M; Omidi Y
Genet Test Mol Biomarkers; 2009 Oct; 13(5):665-70. PubMed ID: 19715474
[TBL] [Abstract][Full Text] [Related]
32. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
33. Genetic polymorphism of CYP2D6 in the Japanese population.
Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
35. Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology.
Eriksson S; Berg LM; Wadelius M; Alderborn A
Assay Drug Dev Technol; 2002 Nov; 1(1 Pt 1):49-59. PubMed ID: 15090156
[TBL] [Abstract][Full Text] [Related]
36. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.
Byeon JY; Kim YH; Lee CM; Kim SH; Chae WK; Jung EH; Choi CI; Jang CG; Lee SY; Bae JW; Lee YJ
Arch Pharm Res; 2018 Sep; 41(9):921-930. PubMed ID: 30191460
[TBL] [Abstract][Full Text] [Related]
37. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
38. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.
Raimundo S; Toscano C; Klein K; Fischer J; Griese EU; Eichelbaum M; Schwab M; Zanger UM
Clin Pharmacol Ther; 2004 Aug; 76(2):128-38. PubMed ID: 15289790
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetics of Cytochrome P450 Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital.
McGrane IR; Loveland JG
J Child Adolesc Psychopharmacol; 2016 May; 26(4):395-9. PubMed ID: 26871369
[TBL] [Abstract][Full Text] [Related]
40. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
